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Purpose: Aromatase inhibitors (AIs) limit the synthesis of oestrogen in peripheral tissues 
thus lowering levels of oestrogen.  The primary aim was to evaluate whether women 
treated with AIs have altered dry eye symptoms and signs. A sub-aim was to investigate 
whether symptoms of dry eye in postmenopausal women were associated with symptoms 
of non-eye pain, ocular pain and self-rated pain perception. 
Methods: This cross-sectional, observational, single visit study recruited 56 postmenopausal 
women (mean age 64.1+7.9 years) and 52 undergoing AI treatment (mean age 66.6+9.0). 
Ocular symptoms (OSDI, MGD14) and pain questionnaires (PSQ, OPAS) were administered 
and signs of dry eye and meibomian gland dysfunction were evaluated.  
Results: Almost half of each group reported dry eye symptoms, defined as OSDI>12 (48% 
control, 46% AI). The PSQ score was significantly higher in the AI group (p=0.04). Neither 
frequency or severity of dry eye (or MGD) symptoms scores were significantly different 
between groups. In the AI group, meibomian gland expressibility score was worse (p=0.003); 
there were no differences in any other signs.  Higher OSDI scores were associated with 
higher OPAS eye-pain scores (r=0.49, p<0.001), but not OPAS non-eye pain (r=0.09, p=0.35). 
Pain perception (PSQ) showed a moderate positive association with OPAS eye-pain (r=0.30, 
p=0.003). 
Conclusions: In this study elevated ocular symptoms were observed in both the AI treated 
and the untreated groups, with no difference between the groups. Women undergoing AI 
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treatment for early stage breast cancer had worse meibum expressibility score and 
increased pain perception compared to an untreated group of women. 
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Dry eye disease (DED) occurs more frequently in women than men.
1,2
 Sex, gender and 
hormones play an important role in dry eye disease and regulation of the ocular surface, as 
reviewed in the TFOS DEWS II report.
2
 Androgens appear to have a positive effect on tear 
production and the ocular surface in humans.
3–5
 However the role of oestrogen is not well 
understood
2,6




Post-menopause, ovarian secretion of oestrogens ceases and it is estimated that 100% of 
oestrogens are synthesised locally in peripheral tissues by intracrinology.
6,8
 Aromatase 
inhibitors (AIs) limit the synthesis of oestrogen from the oestrogen precursor 
androstenedione
9
 in peripheral tissues thus lowering levels of oestrogen. By investigating 
postmenopausal women treated with AIs it may be possible to observe the effects of 
absence of oestrogen on tear production and thus DED and meibomian gland dysfunction 
(MGD).  
Previous investigations of dry eye symptoms in postmenopausal women undergoing 
treatment with AIs showed a two-fold increase in symptoms compared to untreated 
women.
10–12
 It can be hypothesised that reduced oestrogen availability to ocular surface 
tissues impacts the function and/or morphology of the tear producing glands and thus 
results in DED and MGD. However, the effect of aromatase inhibitors on clinical dry eye 
signs has not yet been investigated.  
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The primary aim of this study was to investigate whether treatment with aromatase 
inhibitors impacts clinical signs of DED and /or MGD. This study also aimed to investigate 
whether the associations between symptoms of DED and AIs found by previous studies 
could be replicated, with the addition of specific questionnaires to also assess symptoms of 
MGD and pain. 
Dry eye symptoms and ocular signs are often poorly associated.
13
 Pain 
perception/sensitivity may help to explain the lack of association between dry eye signs and 
symptoms.
14,15
 Sex and gender appear to affect pain reporting, in systemic pain and in DED.
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Therefore, two pain questionnaires were included in this study (Pain Sensitivity 
Questionnaire [PSQ] and Ocular Pain Assessment Survey [OPAS]) to achieve the secondary 
aim, to investigate whether higher symptoms of dry eye were associated with higher 
symptoms of general body pain (OPAS), ocular pain (OPAS) and self-rated pain perception 
(PSQ).  
High pain sensitivity and low pain tolerance, measured with heat stimuli applied to the arm, 
have been shown to be associated with symptoms of dry eye.
15
  This suggests people with 
symptomatic dry eye may be more sensitive to pain and vice versa. Therefore, another 
objective was to investigate whether associations between dry eye symptoms and signs 





This was a cross-sectional, observational, single visit study of postmenopausal women 
treated with AIs and postmenopausal women not undergoing any hormone-based 
treatment.  
The research followed the tenets of the Declaration of Helsinki and informed consent was 
obtained from the participants after explanation of the nature of the study and prior to 
starting the study. The research was approved by the Human Research Ethics Committees of 
St Vincent’s Hospital Sydney and the University of New South Wales. 
PARTICIPANT SELECTION 
Women aged 50 years and over with a minimum of 12 months postmenopause (determined 
as permanent menstrual cessation of at least 12 months)
16,17
 and treated with AIs, were 
recruited from The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney (October 2017 - 
May 2018). The control group comprised of postmenopausal women, not taking hormone 
therapy (including hormone replacement therapy [HRT] or AIs), recruited from the 
University of New South Wales (UNSW) Optometry Clinic in Sydney and nearby community 
(September 2017 - June 2018). Women in the control group were enrolled to correspond to 
the age ranges, and average ages (mean and median), of the women enrolled in the 
treatment group to avoid age as a confounding factor. On the visit day, women in the 
treatment group were seen when they attended for their oncology appointment; the 
control group attended the optometry clinic purely to take part in the research (their 
attendance was in response to the recruitment advertisement, although some participants 
had previously attended the optometry clinic for routine eye exams).   
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Exclusion criteria were: hormone treatment within the preceding 12 months, (other than AI 
in the treatment group); diagnosis with Sjögren Syndrome (revised European Classification 
criteria
18
) or other autoimmune disease; concurrent chemotherapy treatment in the AI 
group or history of chemotherapy in the control group; recent (1 month) ocular or refractive 
surgery; ocular or systemic conditions and/or treatment (topical/systemic) deemed likely to 
significantly impact the ocular surface (including current use of anti-acne medication, eye 
drops to control intra-ocular-pressure (IOP), corticosteroids, immunosuppressants). 
G Power (version 3.0) was used to calculate a sample size based on OSDI
19
 with a moderate 
effect for the difference in OSDI symptoms between the AI and non AI groups (effect size of 
0.5). For 80% power at alpha =0.05 and effect of 0.5, a sample size of 51 per group was 
required. Up to an additional 10% of participants were recruited into each group to account 
for potential missed data. 
PROCEDURES  
All procedures were conducted in a single visit during clinic hours (8am to 5pm).  The clinical 
procedures were performed on the right eye only, in the order from least to most invasive 
(grading scales provided in Supplementary Table 1). 
Questions regarding general health and medication, including duration of AI use and any 
prior history of chemotherapy were conducted verbally. Weight and height were self-
reported and used to calculate body mass index (BMI). Questionnaires were completed by 
the participant on an iPad in the following order: Ocular Surface Disease Index (OSDI)
20,21
 
and MGD Questionnaire (MGD-14)
22
  to assess ocular surface symptoms, PSQ
23
 to assess 
self-rated pain perception, OPAS to assess ocular surface pain, the OPAS non-ocular pain 
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component to assess non-eye pain, 
24
 and the Instant Ocular Symptoms Survey (IOSS)
25
 to 
assess dry eye symptoms at that moment.  
The PSQ assesses self-rated pain perception based on imagined scenarios experienced in 
daily life. 
26
 Scenarios are graded on a scale of 0-10 (no pain-most severe pain imaginable), 
for example: “Q2. Imagine you burn your tongue on a very hot drink.” Therefore, patients 
do not need to be suffering from pain, of any type, to be able to score the imagined pain in 
the scenarios presented in the questions. The PSQ was associated with experimentally 
obtained pain intensity ratings  in healthy individuals.
26
 The PSQ provides three scores: the 
overall pain “perception” score (PSQ-total), scores for “pain perception” to scenarios with 
mild (PSQ-minor) and moderate (PSQ-moderate) pain. 
23
 The OPAS was specifically designed 
to measure intensity of ocular pain of any origin and  provides scores for non-eye pain.
24
 
Slit lamp bio-microscopy was carried out to assess the general ocular surface and eyelid 
health.  
Non-invasive tear break up time (NIBUT) was evaluated using a slit lamp mounted tearscope 
with grid attachment (Easy Tear View +, Easytear s.r.l. Trento, Italy). NIBUT was recorded as 
the mean of three readings at the timepoint when the grid pattern reflected in the tear film 
first distorted.  
Tear volume was measured using a Phenol Red Thread (PRT), (Tianjin Jingming New 
Technological Development Co. Ltd. Tianjin, China).
27
  
Integrity of the cornea and conjunctiva were assessed using vital dye staining (Sodium 
Fluorescein strip [Contacare Ophthalmics & Diagnostics, Gujarat, India] and Lissamine Green 
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strip [Biovison Limited, Dunstabel, UK]) and the Modified Oxford grading scale.
28
 The 
ophthalmic strips were moistened with saline, shaken to remove excess solution and 
applied to the temporal inferior bulbar conjunctiva. Following the initial application of 
lissamine green, Marx line was assessed and graded.
29
 
Prior to stain application, the number of capped meibomian glands were counted and lower 
eyelid telangiectasia was graded as 0 (no telangiectasia) to 3 (>5 telangiectasia)
30–32
 
Expressibility of meibum was assessed using the Meibomian Gland Evaluator (Tear Science 





All data analysis was performed using IBM SPSS Statistics (version 24). Data were tested for 
normality using Shapiro-Wilk tests. Independent samples t–tests and Mann-Whitney U tests 
were used to compare variables between groups. Fisher Exact tests were used to compare 
dry eye symptoms between groups. Partial correlations were used to examine associations 
between variables, controlling for AI use and PSQ. A p=value of <0.05 was considered to be 
statistically significant. AI data was assessed in isolation to examine the effect of 
chemotherapy on variables. 
MAIN OUTCOME MEASURES 
The primary outcome measure for this study was dry eye symptoms, measured with the 






A total of 109 participants were enrolled. One participant from the control group was 
excluded from analysis because she had started taking eye drops to control intra ocular 
pressure (IOP) between the screening and the study visit. Therefore 108 participants were 
included in the analysis, 56 in the control group and 52 in the AI group (Table 1). In the AI 
group, 38 women were taking letrozole (73 %), 7 anastrozole (13.5 %) and 7 exemestane 
(13.5 %). There was no significant difference between the control and AI groups in age, BMI 
or ethnicity (Table 1). All variables showed non-parametric distribution, other than age and 
PSQ scores.  
Table 1. Demographics of test (AI) and control groups. 
Aromatase Inhibitor (AI), Body mass index (BMI), inter quartile range (IQR), standard deviation 
(SD). 
OCULAR SURFACE SYMPTOMS AND PAIN  
Six participants in the AI group did not complete the questionnaires because they needed to 
leave the clinic for transportation reasons. Although these patients could have affected the 
study outcomes, by the exclusion of these patients’ symptom data, this is unlikely as their 






Age (mean, SD, range 
[years]) 
64.1 ± 7.9 (50.5-80.6) 66.6 ± 9.0 (51.9-
93.5) 
0.18 
AI duration (median, 
IQR[years])  
 1.3 [3.0]  
BMI 26.9 ± 6.5 26.8 ± 5.9 0.33 
Ethnicity    
Caucasian 51 (91%) 47 (90%)  
Asian 3 (5%) 2 (4%) 0.81 
Other 2 (4%) 3 (6%)  
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of the control participants reported dry eye symptoms, as defined by an OSDI score >12 
(Figure 1).
36
 There was no significant difference between groups in distribution of OSDI 
scores (p=0.84). There was no significant difference in OSDI, MGD-14 or IOSS scores 
between the AI and control groups, (Table 2). Pain perception measured using the PSQ was 
significantly higher in the AI group than the control group for moderate pain scenarios 
(p=0.045) and total pain (p=0.04) (Table 2 and Figure 2). There were no significant 
differences between groups in any of the OPAS score domains (Table 2).  
Table 2. Group averages for dry eye and pain questionnaires scores.  
Key: 2 weeks (2w), Instant Ocular Symptoms Survey (IOSS), Meibomian Gland Dysfunction 
(MGD-14: 14 questions), Ocular Pain Assessment Survey (OPAS), Ocular Surface Disease Index 
(OSDI), Pain Sensitivity Questionnaire (PSQ), Quality of Life (QOL), 24 hours (24h). 










Dry eye symptom scores      
OSDI (0-100) 9.8 [18.0] 0.0-68.8 10.9 [13.5] 0.0-72.9 0.84 
MGD-14 (0-126) 11.0 [25] 0-96 14.0 [19.3] 0-115 0.63 
IOSS (0-10) 2.0 [2.8] 0-8 1.5 [2.0] 0-6 0.21 
Pain scores      
OPAS  
total(0-200) 
non-eye pain  
severity (0-20)  
QOL (0-60) 
eye pain  
severity 24h (0-30) 
severity 2w (0-30) 
QOL (0-60) 
aggravating factors (0-20) 
























































Pain perception scores Mean ± SD Range Mean ± SD Range  
PSQ  
total (1-170) 
minor pain (0-70) 
moderate pain (0-70) 
 
58.0 ± 21.8 
21.3 ± 11.1 






67.3 ± 23.7 
25.1 ± 12.1 











OCULAR SURFACE AND MGD SIGNS 
Meibomian gland expressibility score was worse in the AI group (p=0.003) (Figure 2, Table 3; 
see also supplementary data Figure 2). There were no significant differences between the AI 
and control groups in tear function, ocular surface staining or other MGD signs (Table 3). 
Table 3. Group averages for clinical signs of dry eye and MGD.  
Key: meibomian gland (MG), non-invasive tear break up time (NIBUT), phenol red thread (PRT).  





Mean ± SD or 
Median [IQR] 
Range Mean ± SD or 
Median [IQR] 
Range  
Corneal Staining (0-5) 0.0 [0.0] 0-1 0.0 [0.0] 0-3 0.91 
Conjunctival staining (0-5) 2.1 + 1.2 0-4 2.2 + 1.0 0-4 0.84 
Tear Function      
NIBUT (seconds) 8.7 + 4.1 2.9-24.7 9.3 + 3.0 4.3-18.1 0.39 
PRT (mm) 11.5 + 7.6 3-35 12.6 + 6.8 1-30 0.22 
MGD      
Capping  0.0 [1.0] 0-8 0.0 [2.0] 0-12 0.18 
Marx Line (0-9) 3.8 + 2.7 0-9 3.5 + 2.2 0-9 0.73 
MG expressibility (0-3) 0 [1] 0-3 1 [1] 0-2 0.003* 
Telangiectasia (0-3) 2.5 + 0.8 0-3 2.7 + 0.7 0-3 0.052 
ASSOCIATIONS 
There was good association between OSDI, MGD-14, IOSS and OPAS eye pain scores (Table 
4). OPAS non-eye pain was weakly associated only with the IOSS score. Increased PSQ score 
was weakly associated with increased OPAS eye, OPAS non-eye and MGD-14. Partial 
correlations showed that neither AI use nor pain sensitivity (PSQ) had any effect on these 
relationships. 
The only significant association between dry eye signs and ocular surface symptoms or pain 
was that between reduced NIBUT and increased MGD-14 score(r=-0.24, p=0.02 [controlling 
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for PSQ r=-0.21 p=0.04, controlling for AI r=-0.24, p=0.015). There was no association 
between AI duration and any of the variables examined. 
Table 4. Summary of significant associations between signs and symptoms of dry eye, MGD and 
pain sensitivity in postmenopausal women when controlling for AI treatment: rho (p value) 
shown. 
Key: Ocular Surface Disease Index (OSDI), Meibomian Gland Dysfunction (MGD-14 Question), 
Instant Ocular Symptom Survey (IOSS), Ocular Pain Assessment Survey (OPAS eye: sum of eye 
pain severity in 24 hours, 2 weeks and effect on quality of life), Pain Sensitivity Questionnaire 
(PSQ). 
 OSDI MGD-14 IOSS OPAS eye OPAS non-eye 
OSDI      
MGD-14 0.75 (<0.001)     
IOSS 0.56 (<0.001) 0.68 (<0.001)    
OPAS eye 0.49 (<0.001) 0.69 (<0.001) 0.57 (<0.001)   
OPAS non-eye 0.09 (0.35) 0.14 (0.16) 0.20 (0.04) 0.09 (0.36)  
PSQ total 0.09 (0.38) 0.25 (0.01) 0.18 (0.07) 0.30 (0.003) 0.23 (0.02) 
EFFECT OF CHEMOTHERAPY 
17 of the 52 (33%) participants in the AI group had a history of prior chemotherapy. These 
participants were significantly younger (61.9 + 6.3 years) than those without a history of 
chemotherapy (70.0 + 9.3 years) (p=0.01). The median duration of AI use was significantly 
shorter in participants with a history of chemotherapy (0.6 years, IQR 3.5, range 0.2-25.0 
years) compared to those without a history of  chemotherapy (1.8 years, IQR 3.0, range 0.2-
7.0 years) (p<0.001). 
There were no significant differences between the two groups for any of the symptoms 
scores, clinical signs of dry eye or MGD (Supplementary Table 2). 
DISCUSSION 
The primary aim of this research was to investigate the effects of reduced oestrogen 
synthesis on dry eye symptoms and signs, in postmenopausal women. No difference in dry 
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eye symptoms scores were found between women treated with AIs compared to untreated 
women, however pain perception scores, measured with the PSQ, were significantly higher 
in the treated group. Meibum was not as clear or as easily expressed in the AI treated 
group.   
In this cross-sectional study, the frequency of dry eye in both AI treated and untreated 
women was higher than that previously reported for the general population.
1
 Almost half of 
the participants in this study reported dry eye symptoms with an OSDI score > 12 and 
approximately a quarter had an OSDI score > 22 (indicating moderate or severe dry eye 
symptoms). 
20,21




The present study did not find dry eye symptoms to be different between postmenopausal 
women undergoing treatment with AIs and untreated women of the same age. This 
contrasts with three previous studies which report symptoms of dry eye to be twice as 
common in women treated with AIs.   Notably, the proportion of  women treated with AIs 
who reported dry eye symptoms in this study (46%) is comparable to that reported by Inglis 
et al. (35%).
12
 However, Inglis et al. report a substantially lower occurrence of dry rye 
symptoms in their untreated group (18%) recruited from a mammography screening clinic in 
the same catchment area. 
12
 A retrospective chart review conducted by Turaka et al. of dry 
eye symptoms in patients presenting to a US cornea service showed that 29% of women 
treated with AIs reported the symptom of ocular irritation or foreign body sensation, 
compared to 9.5% of untreated women.
10
 A much lower rate of dry eye symptoms (4% in AI 
treated women and 2% in untreated women) was reported in a world-wide study of the 
15 
 




To our knowledge, this is the first study to investigate the effects of AI treatment on ocular 
surface signs. Significantly worse meibomian gland expressibility was observed in the AI 
group. Since AI treatment inhibits oestrogen synthesis, this suggests that reduced oestrogen 
levels impair meibomian gland function.  
Our values were comparable to those found by Arita et al. in two different studies, which 
use the same meibum grading method as used in this study; 
34,35
 Arita et al. used a similar 







 also looked at the effect of oestrogens on meibomian glands in 
postmenopausal women and, using a different grading scale to the one used here, they 
found values for expressibility and quality to be comparable to the present study. Three of 
these studies (those by Arita et al. and Ablamowicz et al.) evaluated differences in meibum 
score between two groups of participants with different dry eye or MGD status:  all three 
studies found a difference in score of one grade, which is comparable to the difference 
found between AI and non-AI treated women in this study.
34,35,37
 
 As dry eye signs and symptoms are known to be poorly associated it is not surprising that 
the difference in meibomian gland expressibility score was not reflected in differences in 
symptoms. 
14,15
 NIBUT was not reduced in the AI group in the presence of worse meibomian 
gland expressibility score suggesting changes in meibum appearance may precede an impact 
of tear stability. Other clinical signs were not different between AI and untreated women.  
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The duration of AI use varied from 6 weeks to in excess of ten years. No significant 
association was found between AI duration and any signs and symptoms of dry eye. This 
suggests that once maximum oestrogen suppression is achieved,  at about 3-7 days of AI 
use,
38
 the extent of the effect of AIs on dry eye remains stable. In contrast, Inglis et al. found 
longer AI treatment duration to be weakly associated with higher OSDI scores.
12
 The 
average duration for AI use in the study by Inglis et al. (2.5 years [range 1 month-8 years]) 
was longer than in this study (± 28.6 months, range 4-84) and Turaka et al. found the mean 
length of treatment before dry eye symptoms were self-reported was 14 months.  
This study found no effect of a history of chemotherapy on any signs or symptoms or dry 
eye, which is consistent with results found by Inglis et al. who assessed effect of 
chemotherapy on symptoms.
12
 Chemotherapy is reported to increase dry eye in patients 
while they are undergoing treatment,
39–41




Using heat stimuli, Vehof et al. found high pain sensitivity to be associated with 
symptomatic DED, which implies consideration of pain management is important when 
treating dry eye, in addition to treating the ocular surface.
15
 The PSQ has previously shown 
association with experimentally obtained pain intensity ratings in healthy individuals. 
26
  In 
this study, we investigated the association between PSQ and symptomatic DED. We found 
self-reported pain perception measured with the PSQ was not associated with OSDI scores, 
which is in contrast to increased pain sensitivity measured with heat stimuli associated with 
increased eye symptoms.
15
  Measuring pain sensitivity rather than pain perception appears 
to have an effect on the association with dry eye symptoms. 
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All three dry eye questionnaires were moderately associated with the eye-pain section of 
the OPAS. Although they each ask different questions, all the questionnaires which asked 
about ocular surface symptoms were highly associated. Whilst there was strong association 
between eye symptoms questionnaires, neither the IOSS nor the OSDI were associated with 
self-rated pain perception measured using the PSQ. PSQ scores were significantly associated 
with MGD-14 score, OPAS eye-pain and OPAS non-eye pain.  
To investigate whether pain perception may in part explain the lack of association between 
dry eye signs and symptoms, associations between symptoms and signs were assessed with 
and without controlling for PSQ scores. Associations between dry eye signs and symptoms 
were actually weaker in this study when controlling for pain perception. Pain perception 
does not appear to account for the lack of association between symptoms and signs of dry 
eye.  
In order to test causation, the optimal study design would be a longitudinal study which 
used baseline data prior to treatment and assessed patients at various time points whilst 
undergoing treatment.  However, a longitudinal study of this same cohort has logistical 
complications. Recruitment of the AI cohort was difficult due to the stringent exclusion 
criteria and enrolment in a longitudinal study would be more challenging due to the 
increased requirements from participants, who are undergoing treatment for cancer. Many 
of the participants in this clinical study came to Sydney especially for their oncology 
appointments so timing study visits on schedule to coincide with participants’ return visits 
would be challenging. Some weeks only one or two eligible patients presented to the clinic, 
with no guarantee that they would be willing/able to participate in the study; this was a 
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limitation also encountered by Inglis et al. 
12
 Given the large time and cost investment 
required for such a longitudinal study in this group, we believe that a cross-sectional design 
in the first instance is most appropriate.  
The high level of dry eye symptoms reported in the control group may be a result of some 
selection bias in recruitment of the control group. Untreated participants were recruited 
from the community and UNSW optometry clinic, and it is possible that women 
symptomatic for dry eye self-selected into the study. This limitation can be overcome in 
future studies by consecutive recruitment of patients from other clinics in the same 
catchment area.  
A potential limitation of this study is that participants who experienced side-effects with AI 
use, including dry eye symptoms, may have already discontinued treatment, and thus were 
not included in our sample. Future longitudinal studies, in which every patient put onto AI 
treatment is subject to evaluation after a few weeks of treatment, would address this 
potential bias.  
In this study, to grade meibum, we used a 4 point grading scale used by previous studies to 
explore differences between normal and MGD participants as well as between MGD and 
aqueous deficient dry eye participants.
33,34
 Alternative methods for grading meibomian 
gland function have also been published, including evaluating number of glands expressing 
meibum and objective tests, such as meibography, with gland drop out evaluated using 
image analysis. Unlike diagnostic tests such as the OSDI and tear osmolarity, meibomian 
gland grading tests do not have universally accepted cut off values for a positive diagnosis, 
19 
 
therefore understanding the clinical significance between grades is open to interpretation 
by clinicians and would rely on other clinical signs and symptoms to influence management. 
In conclusion, in this study elevated ocular symptoms were observed in both the AI treated 
and the untreated groups, with no difference between the groups. Women undergoing AI 
treatment for early stage breast cancer had worse meibum expressibility score and 
increased pain perception compared to an untreated group of women. Meibomian gland 
function appears to be negatively affected by AI use and should be evaluated in women 
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FIGURE LEGENDS 
Figure 1. Frequency of occurrence of dry eye symptoms (measured with the OSDI) for 
postmenopausal women treated with aromatase inhibitors and an age-matched untreated 
control group.  
There was no significant difference in frequency of occurrence between the two groups.  
Key: dry eye (DE), moderate (mod), Ocular Surface Disease Index (OSDI). 
 
Figure 2. A) pain sensitivity questionnaire (PSQ) total score and B) meibomian gland 
expressibility score. 
Postmenopausal women undergoing treatment with aromatase inhibitor (AI) and an age-
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